Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 0.63 |
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.63 |
| ▸ | BCL2L2 | Q92843 | 4/20 | 0.58 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | ASPH | Q12797 | 1/20 | 0.55 |
| ▸ | BAD | Q92934 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9952313 | 1.00 | BCL2 (0.63) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 | |
| SCHEMBL1497888 | 0.96 | BCL2 (0.69) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 | |
| SCHEMBL9952345 | 0.96 | BCL2 (0.69) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 | |
| SCHEMBL9951370 | 0.95 | BCL2 (0.62) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 | |
| SCHEMBL9951311 | 0.94 | BCL2 (0.69) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 | |
| SCHEMBL9951379 | 0.92 | BCL2 (0.74) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 | |
| SCHEMBL9951375 | 0.92 | BCL2 (0.74) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 | |
| SCHEMBL1497652 | 0.91 | BCL2 (0.56) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 | |
| SCHEMBL1497649 | 0.91 | BCL2 (0.56) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 | |
| SCHEMBL10166385 | 0.90 | BCL2 (0.71) | BCL2BCL2L1BCL2L2BCL2L11CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | claimed |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | UNITY BIOTECHNOLOGY, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | UNITY BIOTECHNOLOGY, INC. | 2017-10-05 | — | — | US | disclosed |
| US-8809352-B2 | Sulfonamides as inhibitors of Bcl-2 family proteins for the treatments of cancer | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| EP-2475661-B1 | SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281649-A1 | COMPOUNDS AND THERAPEUTIC USES | TP53, NQO1, SHMT2 | BCL2 520/4885BCL2L1 953/4885BCL2L2 1125/4885 |
| US-20120165298-A1 | SULFONAMIDE COMPOUNDS | BCLAF1, BCL2L11, BCL2 | BCL2 3/4885BCL2L1 4/4885BCL2L2 6/4885 |
| US-10195213-B2 | Chemical entities that kill senescent cells for use in treating age-related disease | TP53, CDKN1A, GLA | BCL2 132/4885BCL2L1 464/4885BCL2L2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.